aTyr Pharma Announces Third Quarter 2015 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
aTyr Pharma (LIFE) Trims Q3 Loss
November 11, 2015 7:38 AM ESTaTyr Pharma (NASDAQ: LIFE) reported Q3 EPS of ($0.48), versus ($8.02) reported last year.
For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.
... MoreaTyr Pharma (LIFE) Selects iMod.Fc Molecule as IND Candidate
November 11, 2015 7:37 AM ESTaTyr Pharma (NASDAQ: LIFE) announced that it has selected an Investigational New Drug (IND) Candidate based on an immuno-modulatory and fibro-modulating Physiocrine domain fused to an Fc region of a human antibody, iMod.Fc. The selected iMod.Fc molecule is intended to address patients with severe pulmonary diseases with an immune and fibrotic component.
"The molecule developed in our iMod.Fc discovery program represents a major breakthrough as the first engineered Physiocrine with advantageous pharmaceutical properties... More
